Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

theramex ireland limited - dydrogestérone 10 mg - comprimé - 10 mg - pour un comprimé > dydrogestérone 10 mg - progestatifs - classe pharmacothérapeutique - code atc : g03db01duphaston contient un médicament appelé « dydrogestérone ».la dydrogestérone est une hormone de synthèse.elle est très similaire à l’hormone produite par votre corps, la « progestérone ».les médicaments comme duphaston sont appelés des « progestatifs ».ce médicament est indiqué dans le traitement : des troubles des règles, des douleurs génitales : syndrome prémenstruel, douleurs de règles, de l’endométriose (présence de tissu de la muqueuse utérine en dehors de l’utérus), de la stérilité par insuffisance lutéale, de la ménopause confirmée (cycle artificiel en association avec un estrogène), des mastopathies bénignes.

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - dydrogestérone 10 mg - comprimé - 10 mg - dydrogestérone 10 mg - dydrogesterone

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - oestradiol 1 mg (comprimé blanc); oestradiol 1 mg (comprimé gris); dydrogestérone 10 mg (comprimé gris) - comprimé - 1 mg - 10 mg - dydrogestérone 10 mg; oestradiol 1 mg; oestradiol 1 mg - dydrogesterone and estrogen

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - dydrogesterone - oral tablet - 10mg

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

viatris healthcare limited, ireland damastown industrial park, - dublin - dydrogesterone - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 10mg/tab - dydrogesterone 10mg - dydrogesterone

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - oestradiol 2 mg (comprimé rouge); oestradiol 2 mg (comprimé jaune); dydrogestérone 10 mg (comprimé jaune) - comprimé - 2 mg - 10 mg - oestradiol 2 mg; dydrogestérone 10 mg; oestradiol 2 mg - dydrogesterone and estrogen

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - dydrogesterone 10 mg - tablet - 10 mg - dydrogesterone 10 mg - dydrogesterone

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).

Malta - engelsk - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - dydrogesterone, estradiol - film-coated tablet - dydrogesterone 10 mg estradiol 1 mg - sex hormones and modulators of the genital system